Bicara Therapeutics (BCAX) Net Equity Issued and Repurchased (2023 - 2026)

Bicara Therapeutics' Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $161.8 million for Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $161.8 million; the TTM figure through Mar 2026 stood at $190.2 million (changed N/A YoY), while the FY2025 annual figure was $29.5 million, down 91.13% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $161.8 million, up from $29.5 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $161.8 million in Q1 2026, with the low at -$1.1 million in Q4 2024.
• The 3-year median for Net Equity Issued and Repurchased is $29.5 million (2025), against an average of $63.4 million.
• Peak annual rise in Net Equity Issued and Repurchased reached 2903.99% in 2025, while the deepest fall reached 2903.99% in 2025.
• Bicara Therapeutics' Net Equity Issued and Repurchased stood at -$1.1 million in 2024, then soared by 2903.99% to $29.5 million in 2025, then surged by 448.39% to $161.8 million in 2026.
• Business Quant data shows BCAX's Net Equity Issued and Repurchased at $161.8 million in Q1 2026, $29.5 million in Q4 2025, and -$1.1 million in Q4 2024.